Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-27

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to learn how different forms of a study medication called danuglipron are taken into the blood in healthy adults, following single dose administration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg

NCT06233045

Healthy Subjects

NOT_YET_RECRUITING PHASE1

Daprodustat Bioequivalence and Food Effect Study

NCT03493386

Anaemia

COMPLETED PHASE1

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

NCT06440980

Healthy Obese Overweight +1 more

COMPLETED PHASE1

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

NCT06393127

Healthy

COMPLETED PHASE1

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

NCT00653055

To Determine Bioequivalence Under Fasting Conditions

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

4-Part

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A

Participants will receive a single oral dose of danuglipron on Day 1 of each period

Group Type EXPERIMENTAL

Danuglipron

Intervention Type DRUG

Danuglipron oral tablets

Part B

Participants will receive a single oral dose of danuglipron on Day 1 of each period

Group Type EXPERIMENTAL

Danuglipron

Intervention Type DRUG

Danuglipron oral tablets

Part C

Participants will receive a single oral dose of danuglipron on Day 1 of each period

Group Type EXPERIMENTAL

Danuglipron

Intervention Type DRUG

Danuglipron oral tablets

Part D

Participants will receive a single oral dose of danuglipron on Day 1 of each period

Group Type EXPERIMENTAL

Danuglipron

Intervention Type DRUG

Danuglipron oral tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Danuglipron

Danuglipron oral tablets

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PF-06882961

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older and overtly healthy
* Body mass Index (BMI) between 16-32 kg/m2; and a total body weight \>50 kg (110 lb)

Exclusion Criteria

* Evidence or history of clinically significant medical conditions or laboratory abnormality
* Any condition possibly affecting drug absorption
* Known intolerance/hypersensitivity to a GLP-1 R agonist
* Use of prescription drugs, nonprescription drugs, dietary supplements or herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of danuglipron in each part of the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes